This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demer, L. L. Search for Related Content PubMed PubMed Citation Articles by Demer, L. L.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1565.)
© 2001 American Heart Association, Inc.

Editorials

Boning Up (or Down) on Statins

Linda L. Demer

From the Departments of Medicine and Physiology, University of California Los Angeles School of Medicine, Los Angeles.

Correspondence to Linda L. Demer, MD, PhD, Division of Cardiology, Box 95-167917, UCLA School of Medicine, Los Angeles, CA 90095-1679. E-mail Ldemer@mednet.ucla.edu

Key Words: lipids • bone • statins • osteoporosis

The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase mediates cholesterol biosynthesis by converting HMG-CoA to mevalonic acid. Although the focus has been on its effects on cholesterol, because mevalonic acid is also required for isoprenoid synthesis, it may also affect other important biological processes. Isoprenoids are converted by transferases to farnesyl and geranylgeranyl pyrophosphate, which are used for protein prenylation, a post-translational modification consisting of covalent addition of the isoprenoid side chains at or near the carboxyl terminus of certain proteins. Prenylation directs proteins to associate with membranes and mediates protein-protein interactions, thus contributing to a wide variety of general cell functions, particularly signal transduction. Not all the proteins that undergo prenylation have been identified.

See article, page 1636

It has been suggested that inhibitors of HMG-CoA reductase (statins), widely used for treatment of hyperlipidemia, may have pleiotropic effects through inhibition of protein prenylation. This may account for effects of statins that are independent of lipid lowering.^1,2 However, there is also evidence that the mevalonate pathway is so tightly regulated that prenylation could not be significantly affected without toxic doses of statins.³

The report by Maritz et al⁴ in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology addresses one of the possible pleiotropic effects of statins: modulation of bone metabolism. This possibility was brought to attention when Mundy et al⁵ reported that statins promote bone formation in rats and in calvarial fragments maintained in an organ culture. Although the exact mechanism was not determined, induction of bone morphogenetic protein-2 was observed . . . [Full Text of this Article]

This article has been cited by other articles:

				D. C. Bauer, G. R. Mundy, S. A. Jamal, D. M. Black, J. A. Cauley, K. E. Ensrud, M. van der Klift, and H. A. P. Pols Use of Statins and Fracture: Results of 4 Prospective Studies and Cumulative Meta-analysis of Observational Studies and Controlled Trials Arch Intern Med, January 26, 2004; 164(2): 146 - 152. [Abstract] [Full Text] [PDF]